📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA. Also improved QoL, skin, and MSK outcomes. Post hoc: slowed radiographic progression. Well tolerated & no new safety signals @RheumNow #EULAR2025 #LB0001

📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT. ASAS20: 51% vs 9%; ASAS40: 23% vs 3%. Promising app-based intervention comprising individualised exercise, pt education & disease Mx. @RheumNow #EULAR2025 #LB0002

from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 @RheumNow LB0007

Older adults with chronic MSK pain report lower physical health—but better mental health—than younger peers. Fewer missed work days, too. Is this resilience, adaptation, or shifting expectations with age? POS0402 @RheumNow #EULAR2025

#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31

#EULAR2025 @eular_org update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed @RheumNow RecommendatnII https://t.co/yUrLdk6Eg1

Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA drove lost productivity. Treating RA is not enough —holistic management matters. POS0403 @RheumNow #EULAR2025

🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n

#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL

Self-management of rheum disease is ripe for apps, gamification. How well does it work though? This app (Axia) in axSpA was basically as good as a biologic. Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that #EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89